Actuate Therapeutics (NASDAQ:ACTU) Shares Down 2.8% – Here’s What Happened

Actuate Therapeutics (NASDAQ:ACTU)’s share price fell 2.8% on Wednesday . The stock traded as low as $8.48 and last traded at $8.69. 35,969 shares changed hands during trading, a decline of 12% from the average session volume of 40,781 shares. The stock had previously closed at $8.94.

Actuate Therapeutics Stock Performance

The stock’s fifty day moving average is $7.70.

Actuate Therapeutics (NASDAQ:ACTU) last announced its quarterly earnings results on Tuesday, September 24th. The company reported ($4.20) earnings per share (EPS) for the quarter.

Insider Activity

In other news, major shareholder Leslie W. Kreis sold 24,999 shares of the stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $9.00, for a total transaction of $224,991.00. Following the completion of the sale, the insider now owns 131,248 shares of the company’s stock, valued at $1,181,232. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, major shareholder Leslie W. Kreis sold 24,999 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $9.00, for a total transaction of $224,991.00. Following the completion of the transaction, the insider now directly owns 131,248 shares of the company’s stock, valued at $1,181,232. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Todd S. Thomson sold 18,750 shares of Actuate Therapeutics stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $8.00, for a total transaction of $150,000.00. Following the completion of the sale, the insider now owns 1,184,795 shares in the company, valued at $9,478,360. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Institutional Investors Weigh In On Actuate Therapeutics

A hedge fund recently bought a new stake in Actuate Therapeutics stock. KG&L Capital Management LLC bought a new position in shares of Actuate Therapeutics (NASDAQ:ACTU) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 12,000 shares of the company’s stock, valued at approximately $89,000. KG&L Capital Management LLC owned about 0.06% of Actuate Therapeutics at the end of the most recent quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.